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are counteracted by ETRAs targeting ETB but not ETA receptors. ETB
receptors may also regulate ET-1 levels through changes in ECE-1
expression. We postulate that higher concentrations of treprostinil
may be required to reach clinical efﬁcacy in PAH when combined
with non-speciﬁc ETRAs.
doi:10.1016/j.lfs.2013.12.151
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Background: Transthoracic Doppler echocardiography (DE) is useful
for the screening of pulmonary hypertension (PH), which is often
treated by endothelin antagonist, although recent studies have
suggested that estimation of pulmonary artery pressure (PAP) by DE
is frequently inaccurate. This study aimed to examine that functional
tricuspid regurgitation (TR) with geometric alterations caused by right
ventricular dilatation is involved in the diagnostic error of echocardi-
ography for the assessment of PAP. Methods: We conducted a
retrospective cohort study of consecutive 127 patients (male, n = 58,
mean age of 55 years) who received both echocardiography and right
heart catheterization (RHC) during the 2-year period from November
2008 to October 2010. We deﬁned PH as mean PAP N 25 mmHg at rest
by RHC and “accurate estimated echocardiographic value” when it
remained within 10 mmHg of the invasive measurement. Results: A
total of 75 patients (59%)were diagnosed to have PH by RHC.When the
patients were divided into 3 groups; accurate (n= 52), over-estimate
(n= 63) and under-estimate (n= 12), the diagnosis of PH by RHCwas
42% in accurate, 68% in over-estimate, and 83% in under-estimate
groups (P = 0.004). In echocardiography, right ventricular dimension
was signiﬁcantly larger in over-estimate group (accurate, 30.0 ±
5.7 mm; over, 35.3 ± 8.6 mm; under, 32.8 ± 5.2 mm, P = 0.002), and
the severity of TR was signiﬁcantly worse in over-estimate group
(P b 0.0001). Right atrium tended to be larger in both over-estimate and
under-estimate groups than accurate group (accurate, 38.8 ± 5.7 mm;
over, 42.6 ± 8.49 mm; under, 42.7 ± 6.2 mm, P = 0.073). Conclusions:
Our results indicate that the accuracy of DE is not enough for PAP
evaluation, particularly in patients with PH associated with increased
TR grading and enlarged right heart dimension.
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Since the discovery of ET-1, over-expression of ET-1 has been
demonstrated in patients with pulmonary arterial hypertension
(PAH). In contrast to chronic thromboembolic pulmonary hyperten-
sion (CTEPH), patients with PAH have pulmonary vasculopathy (PV).
PV leads to impaired dilatation of affected pulmonary vessels,
impeding the increase of cardiac output (CO) and stroke volume
(SV) during exercise. Peak O2 uptake shows CO, and peak O2-pulse
shows SV during cardiopulmonary exercise testing (CPX). To
investigate the increase of CO during exercise, we performed CPX
in 12 patients with PAH and 7 patients with CTEPH. Predicted peak
O2 uptake (45.5 ± 8.0 vs. 60.6 ± 13.4%, p b 0.01) and predicted peak
O2-pulse (55.6 ± 7.6 vs. 69.1 ± 6.9%, p b 0.01) were signiﬁcant
higher in CTEPH than PAH. Diffusion capacity for carbon monoxide
(%DLco: 40.3 ± 13.7 vs. 62.2 ± 13.9%, p b 0.01) was also signiﬁcantly
higher in CTEPH than PAH, however there was no correlation
between %DLco and peak O2 uptake or peak O2-pulse. While, there
was no difference in mean pulmonary arterial pressure (mPAP: 31 ±
6.8 vs. 30.1 ± 7.0 mmHg, n.s.), cardiac output (CO: 4.1 ± 0.6 vs. 4.4 ±
0.4 L/min, n.s.), and pulmonary vascular resistance (PVR: 5.2 ± 2.0 vs.
5.2 ± 2.8 wood units, n.s.) at rest. Our data indicate that, regardless of
hemodynamic, both lower peak O2 uptake and peak O2-pulse show PV
impeding the increase of CO during exercise. CPX can predict the onset
of PAH by detection of PV in early stage.
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Introduction: Increased endothelin-1 (ET-1) is a hallmark of
pulmonary arterial hypertension (PAH), and contributes to its patho-
genesis. The factors controlling ET-1 in PAH are poorly understood.
Vascular endothelial growth factor (VEGF) blockade results in PAH-like
lesions in animal models, and has caused PAH in humans. The effects of
VEGF on ET-1 production by human lung blood microvascular
endothelial cells (HMVEC-LBl) are unknown. Methods: We exposed
HMVEC-LBl (Lonza Inc.) in-vitro to human VEGF121 (40 ng/ml) in
serum-free medium for 7 h, in the absence or presence of the VEGF
receptor antagonist, SU5416 (Cayman Chemical, 3 and 10 μM). ET-1
production was measured in the supernatant. Phosphorylation of VEGF
receptor 2 (VEGFR2) was measured by western blotting after exposure
to VEGF ± SU5416 for 5 and 10 min. Results: VEGF effectively caused
VEGFR2 phosphorylation, which was blocked by SU5416. VEGF
decreased ET-1 production by 29%. In the absence of VEGF, SU5146
increased ET-1 production, by 16% at 10 μM, and SU5146 was able to
completely abolish the VEGF effect on ET-1 production. Conclusion:
VEGF may promote vascular health by decreasing ET-1 production in
HVMEC-LBl. Blockade of VEGF signalling by SU5416 increases ET-1
levels and may thereby contribute to the pathogenesis of pulmonary
hypertension seen with VEGF blockade.
doi:10.1016/j.lfs.2013.12.154
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